EdwardDBallMD

Oncology • San Diego, CA

Professor of Hematology & Oncology, UCSD

Join to view full profile

Dr. Ball is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Ball's full profile

Already have an account?

Office
200 W Arbor Dr
San Diego, CA 92103
Phone+1 800-926-8273

Education & Training

Dartmouth-Hitchcock/Mary Hitchcock Memorial HospitalFellowship, Hematology and Medical Oncology, 1982 - 1983
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 1979 - 1981
University of ConnecticutResidency, Internal Medicine, 1976 - 1979
Case Western Reserve University School of MedicineClass of 1976

Certifications & Licensure

NH State Medical License 1982 - Present
CA State Medical License 1998 - 2026
PA State Medical License 1991 - 1998
OH State Medical License 1979 - 1982
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Elected Member The American Society for Clinical Investigation, 1988
Super Doctor SuperDoctors.com
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Breast Cancer Start of enrollment: 2003 Jul 01
Terminated
Phase 2
Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Start of enrollment: 2004 Apr 01
Completed
Phase 2
Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302) Start of enrollment: 2005 Sep 01
Completed
Phase 2
Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML) Start of enrollment: 2005 Jul 01
Completed
Phase 1, Phase 2
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701) Start of enrollment: 2009 Apr 01
Completed
Phase 2
Stem Cell Related Donor Safety Study Start of enrollment: 2010 Jan 01
Completed
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
Completed
Phase 2, Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
Terminated
Phase 3
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Roles: Principal Investigator, Contact
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) Start of enrollment: 2011 Sep 01
Completed
Phase 1, Phase 2
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

A Rare Case of Richter Transformation to Both Clonally Unrelated and Clonally Related Diffuse Large B-Cell Lymphoma in the Same Patient.
Michelle D Don, Carlos Casiano, Huan-You Wang, Mikhail Gorbounov, Wei Song
Case Reports in Hematology. 2024-01-01
9 citations
A global study for acute myeloid leukemia with RARG rearrangement.
Hong-Hu Zhu, Ya-Zhen Qin, Zhang-Lin Zhang, Yong-Jing Liu, Li-Jun Wen
Blood Advances. 2023-07-11
3 citations
Extracorporeal photopheresis for the treatment of chronic graft versus host disease.
Emin Kansu, David Ward, Amber P Sanchez, Robyn Cunard, Mutlu Hayran
Hematology. 2022-12-01

Abstracts/Posters

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
Edward D. Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
Edward D. Ball, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Other